| Literature DB >> 28956184 |
Manabu Natsumeda1, Kunio Motohashi1,2, Hironaka Igarashi3, Takanori Nozawa1,4, Hideaki Abe1, Yoshihiro Tsukamoto1, Ryosuke Ogura1, Masayasu Okada1, Tsutomu Kobayashi1, Hiroshi Aoki1, Hitoshi Takahashi4, Akiyoshi Kakita4, Kouichirou Okamoto1,2, Tsutomu Nakada2, Yukihiko Fujii1.
Abstract
We have previously reported that reliable detection of 2-hydroxyglutarate (2HG) in isocitrate dehydrogenase (IDH)-mutant WHO grade 2 and 3 gliomas is possible utilizing 3.0-T single-voxel magnetic resonance spectroscopy (SVMRS). We set out to determine whether the same method could be applied to detect 2HG in IDH-mutant glioblastoma. Forty-four patients harboring glioblastoma underwent pre-operative MRS evaluation to detect 2HG and other metabolites. Presence of IDH-mutations was determined by IDH1 R132H immunohistochemical analysis and DNA sequencing of surgically obtained tissues. Six out of 44 (13.6%) glioblastomas were IDH-mutant. IDH-mutant glioblastoma exhibited significantly higher accumulation of 2HG (median 3.191 vs. 0.000 mM, p < 0.0001, Mann-Whitney test). A cutoff of 2HG = 0.897 mM achieved high sensitivity (100.0%) and specificity (92.59%) in determining IDH-mutation in glioblastoma. Glioblastoma with high 2HG accumulation did not have significantly longer overall survival than glioblastoma with low 2HG accumulation (p = 0.107, log-rank test). Non-invasive and reliable detection of 2HG in IDH-mutant glioblastoma was possible by 3.0-T SVMRS.Entities:
Keywords: 2-Hydroxyglutarate; Glioblastoma; IDH mutation; Magnetic resonance spectroscopy
Mesh:
Substances:
Year: 2017 PMID: 28956184 DOI: 10.1007/s10143-017-0908-y
Source DB: PubMed Journal: Neurosurg Rev ISSN: 0344-5607 Impact factor: 3.042